Science1 distinct publisher3 min readUpdated
The American Cancer Society killed its October Wine and Spirits Gala under two months after STAT put a $22 million floor on alcohol-industry giving. Judges split the same week on patient records.
The Scientist · Science desk

Compiled by The ScientistSomething wrong?How this is made
The American Cancer Society has cancelled its Wine and Spirits Industry's Gala, an October event at Manhattan's Rainbow Room that had raised money from members of the alcohol industry for decades, a spokesperson confirmed to STAT [1][2]. It landed less than two months after STAT's Isabella Cueto and Lev Facher reported that the charity had for years taken at least $22 million from wine and liquor executives [5][7], which makes this an unusually datable case of a disclosure moving an institution rather than merely embarrassing it.
The wording matters. Spokesperson Michele Money-Carson said ACS "decided to sunset the Wine & Spirits Industry Gala, and the October event will not take place," and framed the move as part of an ongoing evaluation of how the group's events and fundraising align with its mission and prevention guidance [3][4]. The quoted statement does not mention the reporting [15]. So the causal claim rests on the calendar, not on an admission: the confirmation came roughly six to ten weeks before an event that had run for decades [16].
Note also what the number is. The $22 million figure is a floor across multiple years [5], not an annual run rate, so the size of the revenue hole ACS just accepted cannot be computed from what is public. Some critics, including a former cancer society executive, had called the gala an unsettling conflict of interest and inappropriate given alcohol's known links to cancer [6]. Public health professor Michael Siegel put it more bluntly to STAT: "Can you imagine the American Cancer Society hosting a tobacco industry gala? This is basically the same thing," calling the cancellation a wise decision [8].
The same STAT newsletter carried a second governance item pointing the other way [17]. Last week a federal appeals court ruled in favour of the Justice Department's effort to obtain gender-affirming care patient records from the telehealth company QueerDoc, with two of three panel judges finding nothing out of line about the request [9]. Most judges to date have treated such requests as overreaching or brought for an improper purpose [10], and QueerDoc was the first of many quashed requests that federal law enforcement chose to appeal [12]. Some legal experts think the case is a candidate for en banc review by the full court [11].
Meanwhile the DOJ has changed its approach. Since oral arguments in March it has concentrated its subpoena efforts in a Texas district court with a strong conservative reputation [13], while at least one later criminal subpoena, for records from NYU, has been temporarily blocked by a New York federal court [14].
The two stories share a mechanic and invert it. Exposure of an institution's funding sources produced a fast retreat; exposure of individual patients' records is still being litigated venue by venue, with the outcome depending on which panel hears it.
Watch whether QueerDoc's counsel seeks en banc review [11], whether the Texas venue strategy yields rulings that split further from the New York block [13][14], and whether ACS says anything about replacing the gala's revenue or the money already banked [5].
Ranked by verification strength, evidence, and original report placement.
The American Cancer Society quietly canceled its upcoming Wine and Spirits Industry's Gala, a spokesperson confirmed to STAT.
The event, which for decades raised money from members of the alcohol industry at a Manhattan gathering, was set to take place in October at the Rainbow Room.
ACS spokesperson Michele Money-Carson said in an email that the society "decided to sunset the Wine & Spirits Industry Gala, and the October event will not take place."
STAT reported earlier this summer, as part of its "Deadliest Drug" series on the toll of alcohol misuse, that ACS had for years raked in at least $22 million from wine and liquor executives, creating an optics issue for a charity focused on fighting cancer.
Some, including a former executive at the cancer society, said the gala created an unsettling conflict of interest and was inappropriate considering alcohol's known links to cancer.
The cancellation news came less than two months after STAT's Isabella Cueto and Lev Facher reported the group's alcohol-industry fundraising.
Distinct publishers with included, body-backed reporting in this cluster.
2 articles · August 20, 2026
Evidence-backed comparisons of source perspectives and observed adoption signals. Read the methodology
Which Builder, Operator, and Investor concerns the observed source mix emphasized—not a truth score.
Evidence, demonstrated adoption, hype gap, incentives, and confidence are assessed independently, each on its own current evidence. How these are measured.
Named on-record confirmation, thin on second sources
The core fact is as well evidenced as a single-outlet story gets: a named ACS spokesperson confirming cancellation in a directly quoted email, plus a quantified prior investigation ($22 million floor) and a named outside expert. It is capped because every source is STAT, the causal link to the reporting is implied rather than documented, and the litigation thread cites no named courts, case numbers, or documents.
One confirmed institutional action, no sector spread
There is a real, dated behavior change - a decades-old event terminated before its scheduled date - which is more than an announcement of intent. But the sources show exactly one organization acting, give no figure for the revenue foregone, and provide no evidence that other charities, sponsors, or ACS's remaining alcohol-industry relationships have changed. Adoption is therefore concrete but narrow.
Causation implied, not shown
Mildly overstated. The framing in both the cluster headline material and the newsletter foregrounds that the cancellation 'came less than two months after' STAT's $22 million finding, inviting a causal read that no source establishes; ACS's quoted statement cites only mission alignment. The underlying facts, however, are accurate and on the record, so the gap is small rather than severe.
Publisher reporting on its own reporting's effect
STAT is both the sole publisher and the author of the 'Deadliest Drug' investigation credited in the framing, and the newsletter names its own reporters as the cause-adjacent actors - a clear self-interest in presenting the cancellation as an outcome of its journalism. ACS also has an incentive to attribute the decision to routine mission review rather than to pressure. Both incentives are visible on the page rather than hidden, which keeps this from scoring higher.
Core fact solid, interpretation and legal thread soft
High confidence that the gala was cancelled and that the $22 million figure was previously reported, since both rest on quoted, attributed material. Lower confidence in the causal story, in what the decision implies for ACS's wider fundraising, and in the litigation details, which are summarized without named courts or filings and include an expert-speculation forecast.
Follow any of these and your For You feed starts watching them — no settings page required.
science
A vaccine communicator's testable claim: hesitancy answers to burden, not to better facts1 distinct publisher
product
The hearing date is the case: Disney wants a judge before the FCC starts the clock1 distinct publisher
invest
556 wallets, 78,496 bets: Polymarket's insider problem now has a denominator1 distinct publisher
invest
Washington licenses private hacking, and hands the contractor the liability1 distinct publisher